DBVT

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Mohideen PharisChief Medical Officer $705k145k shares SellJan 29, 2026 $2.6K534 shares $4.86 --
Baker Bros. Advisors LPDirector --25M shares Grant / ExerciseJan 12, 2026 Disclosure amount unavailable25M shares -- --
Baker Bros. Advisors LPDirector --2.3M shares Grant / ExerciseJan 12, 2026 Disclosure amount unavailable2.3M shares -- --
EPIC Bpifrance10% Owner $31M7.3M shares SellDec 18, 2025 $5.4M1.3M shares $4.19 --
EPIC Bpifrance10% Owner $42M8.6M shares SellDec 17, 2025 $9.9M2M shares $4.84 --
EPIC Bpifrance10% Owner $45M8.6M shares SellDec 17, 2025 $211.2K40k shares $5.28 --

News

globenewswire.comDBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comJun 9

globenewswire.comDBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026globenewswire.comJun 8

globenewswire.comDBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comJun 5

globenewswire.comDBV Technologies Announces the Results of its 2026 Combined General Meetingglobenewswire.comJun 3

globenewswire.comDBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergyglobenewswire.comJun 2

Trade DBVT

About DBV Technologies S.A.

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

CEO: Daniel Tassé
IPO Date: Oct 22, 2014

Market Data

Market data refresh is queued when this stock page is viewed.

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsJul 29

EPS est. -0.12